Close Menu

research grant

The firm will use the funding to develop a high-throughput screening system for cancer therapeutics.

The Research Initiative in Newborn Screening program will give $2 million in 2011 to support studies of diseases that could potentially be addressed with more and enhanced newborn screening tools.

The Instrument Development for Biological Research program will give $3 million in 2011 for innovations that will transform or improve research technologies.

The grants will fund research into the metabolic basis of heart failure, as well as the role played by beta-adrenergic receptors on fat cells in regulating growth not typically associated with adrenaline.

The grants will fund projects seeking to validate novel molecular targets for disease-modifying interventions for Huntington's disease.

Three intertwined research efforts at CSU will aim to understand how genes control cellular behavior and the role of nucleosomes in the process.

The Biodesign Institute will use an NIDDK grant to develop and validate protein biomarkers for predicting risk of type 2 diabetes.

The company plans to use the $1 million Phase II funding this year, and another $1 million in 2011, to continue developing its SnapPath live tumor cell testing system.

The program is aimed at funding 30 investigators seeking to develop assays that can be miniaturized, automated, and used for screening small molecules.

The institute plans to fund development of new technologies for understanding NHP major histocompatibility complex genes for use in research that could apply to humans.


The Wall Street Journal looks into FamilyTreeDNA's handling of genetic genealogy searches by law enforcement.

In a point-counterpoint in the Boston Globe, researchers discuss the potential of gene editing to prevent Lyme disease, but also the pitfalls of doing so.

MIT's Technology Review reports that researchers hope to develop a CRISPR-based pain therapy.

In Science this week: atlas of malaria parasites' gene expression across their life cycles, and more.